@article{34f262cba0d745dfb4f2e83c36f2c9a3,
title = "Primary Therapy of Waldenstr{\"o}m Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180",
author = "Treon, \{Steven P.\} and Leukothea Ioakimidis and Soumerai, \{Jacob D.\} and Patterson, \{Christopher J.\} and Patricia Sheehy and Marybeth Nelson and Michael Willen and Jeffrey Matous and John Mattern and Diener, \{Jakow G.\} and Keogh, \{George P.\} and Myers, \{Thomas J.\} and Andy Boral and Ann Birner and Esseltine, \{Dixie L.\} and Ghobrial, \{Irene M.\}",
note = "Purpose We examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in patients with symptomatic, untreated Waldenstr{\"o}m macroglobulinemia (WM). Patients and Methods A cycle of therapy consisted of bortezomib 1.3 mg/m2 intravenously; dexamethasone 40 mg on days 1, 4, 8, and 11; and rituximab 375 mg/m2 on day 11.",
year = "2009",
month = aug,
day = "10",
doi = "10.1200/JCO.2008.20.4677",
language = "American English",
volume = "27",
journal = "Journal of Clinical Oncology",
number = "23",
}